FDA-cleared profile

uAngio AVIVA CX

Shanghai United Imaging Healthcare Co.,Ltd. · Fluoroscopy/Angiography · FDA-cleared (510(k))

Authorized purpose: uAngio AVIVA CX provides image guidance for diagnostic, interventional, and surgical procedures, including cardiac, neuro, vascular, nonvascular, rotational angiography, and whole-body radiographic or fluoroscopic procedures.

Clinical role
Acquires, displays, processes, stores, and communicates angiographic and fluoroscopic images for procedural guidance.
Images and patients
Fluoroscopy/Angiography · Whole body; cardiac, neuro, vascular and non-vascular anatomy
Key limitation
Keep in mind: The supported procedures, anatomy, patient table, radiation, detector, tube, and system configuration limits apply; clinicians control acquisition and radiation and retain responsibility for diagnosis and intervention.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: uAngio AVIVA CX provides image guidance for diagnostic, interventional, and surgical procedures, including cardiac, neuro, vascular, nonvascular, rotational angiography, and whole-body radiographic or fluoroscopic procedures.
  • Which images or clinical context are in scope?Modality: Fluoroscopy/Angiography Anatomy or clinical context: Whole body; cardiac, neuro, vascular and non-vascular anatomy Input: Patient registration and administrative information plus X-ray angiographic or fluoroscopic acquisition from the C-arm, detector, generator, and associated system components.
  • Who uses it?Intended users: Trained radiologists, interventional clinicians, surgeons, and other qualified healthcare professionals who operate angiographic X-ray systems.
  • What does the software produce?Output: 2D and 3D displayed or postprocessed images, imported or archived studies, procedural views, and uSpace or uLingo-assisted system interactions.
  • What is its most important limitation?Key limitation: The supported procedures, anatomy, patient table, radiation, detector, tube, and system configuration limits apply; clinicians control acquisition and radiation and retain responsibility for diagnosis and intervention.

Clinical takeaway. Clinical role: uAngio AVIVA CX provides image guidance for diagnostic, interventional, and surgical procedures, including cardiac, neuro, vascular, nonvascular, rotational angiography, and whole-body radiographic or fluoroscopic procedures.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports non-clinical testing showing compliance with listed standards and bench testing of each key feature, such as CBCT. Neuro registration mTRE was less than 1mm; for stitching, all mTREs were smaller than the pixel diagonal distance and the average score was 2.95. In a clinical image evaluation of sample images from hospitals, an ADR certified radiologist used a five-point scale; each image received a score of ≥ 3 and a PASS result. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
uAngio AVIVA CX provides image guidance for diagnostic, interventional, and surgical procedures, including cardiac, neuro, vascular, nonvascular, rotational angiography, and whole-body radiographic or fluoroscopic procedures.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Acquires, displays, processes, stores, and communicates angiographic and fluoroscopic images for procedural guidance.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Patient registration and administrative information plus X-ray angiographic or fluoroscopic acquisition from the C-arm, detector, generator, and associated system components.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
2D and 3D displayed or postprocessed images, imported or archived studies, procedural views, and uSpace or uLingo-assisted system interactions.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Diagnostic and interventional angiography suites, catheterization laboratories, operating rooms, and other procedure settings.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Trained radiologists, interventional clinicians, surgeons, and other qualified healthcare professionals who operate angiographic X-ray systems.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The supported procedures, anatomy, patient table, radiation, detector, tube, and system configuration limits apply; clinicians control acquisition and radiation and retain responsibility for diagnosis and intervention.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports non-clinical testing showing compliance with listed standards and bench testing of each key feature, such as CBCT. Neuro registration mTRE was less than 1mm; for stitching, all mTREs were smaller than the pixel diagonal distance and the average score was 2.95. In a clinical image evaluation of sample images from hospitals, an ADR certified radiologist used a five-point scale; each image received a score of ≥ 3 and a PASS result. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Non-clinical tests were conducted to verify that the proposed device met all design specifications as it is Substantially Equivalent (SE) to the predicate device. The test results demonstrated that the proposed device complies with the following standards:" … "Additional non-clinical tests are conducted for each key feature to ensure safe and effective integration into the system: Feature Bench Testing Performed Cone Beam The bench tests evaluate the performance of CBCT.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports non-clinical testing showing compliance with listed standards and bench testing of each key feature, such as CBCT. Neuro registration mTRE was less than 1mm; for stitching, all mTREs were smaller than the pixel diagonal distance and the average score was 2.95. In a clinical image evaluation of sample images from hospitals, an ADR certified radiologist used a five-point scale; each image received a score of ≥ 3 and a PASS result. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Non-clinical tests were conducted to verify that the proposed device met all design specifications as it is Substantially Equivalent (SE) to the predicate device. The test results demonstrated that the proposed device complies with the following standards:" … "Additional non-clinical tests are conducted for each key feature to ensure safe and effective integration into the system: Feature Bench Testing Performed Cone Beam The bench tests evaluate the performance of CBCT.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K243376 FDA evidence package for uAngio AVIVA CX

  • DesignFDA 510(k) system verification, validation, and applicable medical electrical and imaging standards testing.
  • PopulationThe system components, supported angiographic procedures, and image-guidance functions described in the exact FDA material.
  • Scopeexact submission
  • Tested versionuAngio AVIVA CX configuration described in K243376
  • IndependenceSponsor or vendor study

K243376

No product-specific AI clinical performance endpoint is promoted from this decision material.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K243376 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Patient registration and administrative information plus X-ray angiographic or fluoroscopic acquisition from the C-arm, detector, generator, and associated system components.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K243376: uAngio AVIVA CX

  2. Routing

    Source context, not route validation: The FDA material describes patient registration, image acquisition, 2D/3D viewing and postprocessing, import, archiving, filming, and the uSpace camera and uLingo voice-control functions.

    Scope: Exact FDA submission. This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K243376: uAngio AVIVA CX

  3. AI processing

    Source context, not route validation: The FDA material describes a physical angiographic X-ray system with C-arm, table, generator, tube, detector, monitors, and control modules; current room configuration, service, security, and interoperability remain unverified.

    Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA decision material; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K243376: uAngio AVIVA CX

  4. Returned objects

    Source context, not route validation: 2D and 3D displayed or postprocessed images, imported or archived studies, procedural views, and uSpace or uLingo-assisted system interactions.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K243376: uAngio AVIVA CX

  5. Viewer/worklist/report

    Unresolved route: 2D and 3D displayed or postprocessed images, imported or archived studies, procedural views, and uSpace or uLingo-assisted system interactions.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K243376: uAngio AVIVA CX

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA material describes a physical angiographic X-ray system with C-arm, table, generator, tube, detector, monitors, and control modules; current room configuration, service, security, and interoperability remain unverified.
  • Exact FDA submission
  • Checked 2026-09-04

This is the release-level boundary described in the exact FDA decision material; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

Integration
The FDA material describes patient registration, image acquisition, 2D/3D viewing and postprocessing, import, archiving, filming, and the uSpace camera and uLingo voice-control functions.
  • Exact FDA submission
  • Checked 2026-09-04

This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Security
United Imaging Healthcare's cybersecurity page lists a secure development lifecycle and controls: firewall, encrypted connections, OS hardening, antivirus, patches, authentication, audit log, disk and transmission encryption. Company-level, not release-specific.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Training
Only Trained radiologists, interventional clinicians, surgeons, and other qualified healthcare professionals who operate angiographic X-ray systems should operate or interpret the product; local onboarding must cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K243376 by exact hardware, software, model, algorithm version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: The supported procedures, anatomy, patient table, radiation, detector, tube, and system configuration limits apply; clinicians control acquisition and radiation and retain responsibility for diagnosis and intervention.
  • Exact FDA submission
  • Checked 2026-09-04

Buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K243376 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The FDA material describes a physical angiographic X-ray system with C-arm, table, generator, tube, detector, monitors, and control modules; current room configuration, service, security, and interoperability remain unverified.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA material describes patient registration, image acquisition, 2D/3D viewing and postprocessing, import, archiving, filming, and the uSpace camera and uLingo voice-control functions.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The supported procedures, anatomy, patient table, radiation, detector, tube, and system configuration limits apply; clinicians control acquisition and radiation and retain responsibility for diagnosis and intervention.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K243376 by exact hardware, software, model, algorithm version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243376
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Fluoroscopy/Angiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Whole body; cardiac, neuro, vascular and non-vascular anatomy
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-04-28
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
32Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The discovery snapshot contains no PubMed or ClinicalTrials.gov candidates for K243376; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor documentation, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K243376: uAngio AVIVA CX

    U.S. Food and Drug Administration - Published 2025-04-28 - Accessed 2026-09-04

    Scope: identity, productIdentity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. United Imaging Healthcare Cybersecurity

    United Imaging Healthcare - Accessed 2026-10-25

    Scope: security

Research history

  1. K243376 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252099

Trinias

Shimadzu Corporation

Authorized purpose: Trinias is an interventional fluoroscopic X-ray system for diagnostic and interventional angiography, including cardiac, neurovascular, abdominal, peripheral, rotational, multipurpose, and whole-body radiographic or fluoroscopic procedures.

Modality
Fluoroscopy/Angiography
Anatomy
Heart, neurovascular, abdominal, peripheral vessels, and whole body
Decision
2026-03-24
FDA-cleared K253614

EchoNavigator R5.0

Philips Medical Systems Nederland B.V.

Authorized purpose: EchoNavigator R5.0 supports an interventionalist or surgeon during cardiovascular treatment by combining live X-ray and live echocardiographic information.

Modality
Fluoroscopy/Angiography
Anatomy
Heart and cardiovascular structures
Decision
2026-03-17
FDA-cleared K253584

Alphenix, INFX-8000V/B, INFX-8000V/S, V9.6 with aEvolve Imaging (FOV Extension)

Canon Medical Systems Corporation

Authorized purpose: Alphenix and INFX-8000V/B,S V9.6 with aEvolve FOV Extension are digital radiography and fluoroscopy systems for diagnostic and interventional angiography, with labeled real-time AI Denoising and MFP signal-enhancement functions.

Modality
Fluoroscopy/Angiography
Anatomy
Heart, brain, abdomen, and lower-extremity vessels
Decision
2026-03-10
FDA-cleared K252500

CARA System

Cara Medical, Ltd.

Authorized purpose: CARA assists adult structural-heart and conduction-system procedure planning by segmenting preprocedural CT, visualizing cardiac chambers and conduction landmarks, and overlaying a reviewed three-dimensional roadmap on live fluoroscopy.

Modality
Fluoroscopy/Angiography
Anatomy
Heart/Cardiovascular
Decision
2026-02-20

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history